explore -WSS

explore

author：fashion 2025-08-11 05:32:37 - browse：2839

Susan Galbraith of AstraZeneca gestures while speaking – pharma coverage from STAT — Susan Galbraith, AstraZeneca’s head of cancer research and development, speaks at a STAT event in 2023. Marie Miller for STAT

CHICAGO — AstraZeneca’s head of cancer research and development, Susan Galbraith, is British, and prone to a particularly British style of understatement. She doesn’t boast loudly. But she did come to this year’s annual meeting of the American Society of Clinical Oncology wearing a small lapel pin with the numeral 6 and the “AZ” corporate logo.

That pin represents the number of years in a row that the London-based drug giant has had a presentation in the ASCO plenary, the conference’s biggest showcase for new data. This year, the company has two.

Scientific credibility is great, of course. But AstraZeneca’s shareholders want something else: return on investment.

STAT+ Exclusive Story

Already have an account? Log in

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

Already have an account? Log in

Monthly

$39

Totals $468 per year

$39/month Get Started

Totals $468 per year

Starter

$30

for 3 months, then $39/month

$30 for 3 months Get Started

Then $39/month

Annual

$399

Save 15%

$399/year Get Started

Save 15%

11+ Users

Custom

Savings start at 25%!

Request A Quote Request A Quote

Savings start at 25%!

2-10 Users

$300

Annually per user

$300/year Get Started

$300 Annually per user

View All Plans

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： How one medical school became remarkably diverse
Next article： Why doctors need education on FDA device approval process

focus

WSS

STAT's guide to the next generation of CAR

AI generated plenty of interest at JPM but not a lot of trust

The strategy behind pharma's lawsuits over drug pricing reform

Parkinson’s finding may lead to tests and, someday, treatments

Eli Lilly, Pfizer, and others want in on the online prescription market

Weight bias in eating disorder treatment complicated by new weight loss drugs

hotspot

explore

This article is exclusive to STAT+ subscribers

Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

explore

Jerome Adams on the need for new antivirals for Covid

Biotech venture capitalists face new demands from investors

Malaria cases in Florida and Texas: Here’s what you need to know

Weight bias in eating disorder treatment complicated by new weight loss drugs

Medical records are filled with copy

Paxlovid study fails to answer questions over benefit for broader groups

As demand for Covid shots wanes, Moderna seeks its next success

Prior authorization will have to move faster under new Biden rule

Medical records are filled with copy

Think you might have Covid

entertainment

Death of patient in Alzheimer’s trial raises question of possible risks

New guidelines on severe brain injury complicate already difficult decisions

Donald Trump's relentless attacks on special counsel Jack Smith

Colonoscopy at 40? Study finds a possible benefit

What to make of Gilead’s Trodelvy troubles and Elevation Oncology’s rise

Humana cuts profit projections as Medicare Advantage costs soar

entertainment

focus

Wikipedia

focus